Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women

Journal of Clinical Pharmacology

Volumn 38, Issue 12, 1998, Pages 1137-1143

  Tsunoda, Shirley M ^a,b   Harris, Robert Z ^a,c   Mroczkowski, Patrick J ^a,d   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PREDNISOLONE; PREDNISOLONE SODIUM PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ERYTHROMYCIN; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POSTMENOPAUSE; PREDNISOLONE;

EID: 0032428812     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet 1996;30:141-179.
2. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR: Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269: 1513-1518.
3. Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI: Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 1984;310:1639-1643.
4. Amsden GW: Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995;29:906-917.
5. Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E: Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995;35:188-190.
6. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM: Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995;36:107-114.
7. Guengerich FP: Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 1989;29: 241-264.
8. Watkins PB: Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990;10:235-250.
9. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239.
10. Austin KL, Mather LE, Philpot CR, McDonald PJ: Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-279.
11. Fishman J, Bradlow HL, Schneider J, Anderson KE, Kappas A: Radiometric analysis of biological oxidations in man: sex differences in estradiol metabolism. Proc Natl Acad Sci U S A 1980; 77:4957-4960.
12. Hunt CM, Westerkam WR, Stave GM: Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-283.
13. Lemmens HJM, Burm AGL, Hennis PJ, Gladines MPPR, Bovill JG: Influence of age on the pharmacokinetics of alfentanil. Clin Pharmacokinet 1990;19:416-422.
14. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E, Ferry JJ, et al: Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54:402-414.
15. Meffin PJ, Brooks PM, Sallustio BC: Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol 1984;17:395-404.
16. Gustavson LE, Legler UF, Benet LZ: Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986;62:234-237.
17. Harris RZ, Tsunoda SM, Mroczkowski P, Wong H, Benet LZ: The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996;59:429-435.
18. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988;263:424-436.
19. Yun CH, Wood AJ, Guengerich FP: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance. Anesthesiology 1992;77:467-474.
20. Rubio A, Cox C: Sex, age and alfentanil pharmacokinetics. Clin Pharmacokinet 1991;21:81-82.
21. Frey FJ, Frey BM, Benet LZ: Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma. Clin Chem 1979;25:1944-1947.
22. Hale VG, Benet LZ: Prednisolone and prednisolone exhibit linear extraction in perfused rabbit liver. Drug Metab Dispos 1991; 19:87-93.
23. Frey FJ, Frey BM, Greither A, Benet LZ: Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther 1980;215:287-291.
24. Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NG: Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci 1983;72:1442-1446.
25. Benet LZ, Galeazzi RL: Noncompartmental determination of the steady state volume of distribution. J Pharm Sci 1979;68: 1071-1074.
26. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-697.
27. Rowland M, Tozer TN: Clinical Pharmacokinetics. Third edition. Media, PA: Williams & Wilkins, 1995.
28. Etienne MC, Milano G, Rene N, Benedetti MS, Efthymiopoulos C, Vo Van ML, et al: Improved bioavailability of a new oral preparation of medroxyprogesterone acetate. J Pharm Sci 1991;80: 1130-1132.
29. Back DJ, Madden S, Orme ML: Gastrointestinal metabolism of contraceptive steroids. Am J Obstet Gynecol 1990;163:2138-2145.
30. Benet LZ, Øie S, Schwartz JB: Appendix II: design and optimization of dosage regimens; pharmacokinetic data. In, Hardman JG, Limbird LE, Molinoff PB, Ruddon RWS (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. Ninth edition. New York: McGraw Hill, 1996;1707-1792.
31. Hollander AAMJ, van Rooij J, Lentjes EGWM, Abrouw F, van Bree JB, Schoemaker RC, et al: The effect of grapefruit juice on cyclosporine and prednisolone metabolism in transplant patients. Clin Pharmacol Ther 1995;57:318-324.
32. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ: The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-129.
33. Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, et al: P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994;56:253-260.
34. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB: The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992;51:229-238.
35. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al: Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-1979.
36. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH, Berthou F: Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 1992;44:1745-1756.
37. Bologa M, Tang B, Klein J, Tesoro A, Koren G: Pregnancy-induced changes in drug metabolism in epileptic women. J Pharmacol Exp Ther 1991;257:735-740.
38. Lander CM, Eadie MJ: Plasma antiepileptic drug concentrations during pregnancy. Epilepsia 1991;32:257-266.
39. Prior JC: Progesterone as a bone-trophic hormone. Endocr Rev 1990;11:386-398.
40. 3H triamcinolone acetonide to a ligand binding domain on the glucocorticoid receptor complex in cytosol fractions of brain and liver from the rat with intact adrenals. Brain Res 1995; 685:105-116.
41. Chasserot-Golaz S, Beck G: How the potency of the steroid RU486 is related to P450 activities induced by dexamethasone and phenobarbital in rat hepatoma cells. J Steroid Biochem Mol Biol 1992;41:653-657.